Capital Impact Advisors’s Kyntra Bio KYNB Stock Holding History

Capital Impact Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,264	Closed	-$1.5M	–	134
2017 Q4	$1.5M	Hold	1,264	–	–	0.65%	65
2017 Q3	$1.7M	Sell	1,264 -87	-6%	-$91.7K	0.76%	43
2017 Q2	$1.09M	Sell	1,351 -517	-28%	-$360K	0.5%	107
2017 Q1	$1.15M	Buy	1,868 +149	+9%	+$90.7K	0.46%	121
2016 Q4	$920K	Hold	1,719	–	–	0.38%	142
2016 Q3	$890K	Hold	1,719	–	–	0.38%	137
2016 Q2	$705K	Hold	1,719	–	–	0.33%	181
2016 Q1	$915K	Buy	1,719 +1,305	+315%	+$650K	0.44%	110
2015 Q4	$315K	Hold	414	–	–	0.15%	239
2015 Q3	$227K	Hold	414	–	–	0.12%	234
2015 Q2	$243K	Hold	414	–	–	0.11%	248
2015 Q1	$325K	Buy	+414	New	+$321K	0.15%	234

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Capital Impact Advisors's KYNB Position: Q1 2018 in Review

Capital Impact Advisors sold out of Kyntra Bio (KYNB) in Q1 2018, closing a stake of 1,264 shares — an estimated $1.5M sold.

Capital Impact Advisors first reported a position in KYNB in Q1 2015 and held it in 12 quarters. The position peaked at $1.7M in Q3 2017. 193 funds tracked by Wall St. Rank hold KYNB as of Q1 2018.

Capital Impact Advisors reported no remaining Kyntra Bio position as of Q1 2018 after selling out during the quarter.
Capital Impact Advisors sold 1,264 Kyntra Bio shares in Q1 2018, an estimated $1.5M.
Capital Impact Advisors first reported a position in Kyntra Bio in Q1 2015 and held it in 12 quarters.
Capital Impact Advisors's Kyntra Bio position peaked at $1.7M in Q3 2017.
193 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2018.

Based on Capital Impact Advisors's 13F filing for Q1 2018, filed 11 Apr 2018.